Ionis Pharmaceuticals received FDA approval that further expands Tryngolza (olezarsen) for adults with severe hypertriglyceridemia, widening the drug’s commercial address. The approval came after phase III data released last September, and Ionis positioned the label expansion as a key milestone in its broader shift toward developing and commercializing assets in-house.